Ipamorelin vs GHRP-2 vs GHRP-6: Ghrelin Mimetic Comparison

Ipamorelin vs GHRP-2 vs GHRP-6: Selectivity Profiles and GHSR-1a Binding in Preclinical Research

This content is a research reference summary only. All data described are derived from peer-reviewed pharmacological and preclinical studies. No content here constitutes medical advice, clinical guidance, or recommendation for human administration of any compound.

Growth hormone secretagogues (GHS) of the peptide class — including ipamorelin, GHRP-2 (growth hormone-releasing peptide-2, also known as pralmorelin), and GHRP-6 — all act as agonists at the ghrelin receptor, formally designated GHSR-1a (growth hormone secretagogue receptor type 1a). Despite sharing this receptor target and the primary pharmacological effect of GH secretagogue activity, the three compounds differ meaningfully in receptor selectivity, off-target hormonal effects, and secondary pharmacological actions. These differences are pharmacologically significant for research models in which endpoint confounding by cortisol, prolactin, or appetite-related signaling is a concern.

Much of the foundational selectivity work was conducted in the laboratories of Cyril Bowers and colleagues at Tulane University, who pioneered the GHRP class from the early 1980s through the 2000s.

GHSR-1a Receptor Biology

The ghrelin receptor (GHSR-1a) is a Gαq-coupled GPCR expressed predominantly in hypothalamic and pituitary tissue, with peripheral expression in pancreas, heart, adrenal gland, and gut. Endogenous ghrelin — the octanoylated 28-amino acid peptide produced primarily by gastric X/A-like cells — is the natural ligand. GHSR-1a activation in the pituitary stimulates GH secretion via phospholipase C and downstream PKC/intracellular calcium cascades, acting synergistically with GHRH input.

The synthetic GHRPs were developed as non-ghrelin GHSR-1a ligands with selective GH-secreting properties. Their binding kinetics, selectivity, and downstream pathway engagement differ from endogenous ghrelin in ways that produce distinct secondary pharmacological profiles.

GHRP-6: The Prototypical Peptide GHS with Appetite and Gastric Effects

GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂) was among the first synthetic peptide GHS compounds demonstrated to stimulate GH secretion in humans, as reported by Bowers et al. (1984, Endocrinology). As a hexapeptide, GHRP-6 binds GHSR-1a with high affinity (Ki approximately 4 nM in anterior pituitary membrane assays) and robustly stimulates pulsatile GH release.

Importantly, GHRP-6 shares substantial structural and functional overlap with ghrelin itself, and retains ghrelin-like peripheral receptor activity that translates into appetite stimulation and gastric motility enhancement in preclinical models. Takaya et al. (2000, Nature Medicine) originally characterized ghrelin's role in appetite regulation through GHSR-1a in the hypothalamus; GHRP-6 activates similar appetite pathways via NPY/AgRP neurons in the arcuate nucleus, leading to dose-dependent hyperphagia in rodent models.

GHRP-6 also elevates cortisol and prolactin in humans, an effect attributed to GHSR-1a or cross-reactive receptor activity in the adrenal cortex and lactotroph cells respectively (Arvat et al., 1997, Journal of Clinical Endocrinology and Metabolism). These off-target hormonal effects can confound experimental endpoints in studies targeting GH axis biology exclusively.

GHRP-2: Higher Potency, Retained Cortisol Co-Elevation

GHRP-2 (D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH₂, also known as pralmorelin) was developed as a structurally modified second-generation GHRP with improved GH-stimulating potency relative to GHRP-6. Binding studies by Bowers et al. (1994, Journal of Medicinal Chemistry) and by Howard et al. (1996, Science, describing GHSR-1a cloning) confirmed GHRP-2 as a high-affinity GHSR-1a agonist with Ki values in the 1–3 nM range, representing a 2–4-fold improvement in binding affinity over GHRP-6.

In clinical pharmacology studies, GHRP-2 consistently produces greater peak GH levels than GHRP-6 at equivalent molar doses, and has been used as a diagnostic tool for GH reserve assessment (pralmorelin stimulation test, used in Japan and parts of Europe). Keller et al. (2007, Growth Hormone & IGF Research) validated pralmorelin as a reliable provocative test for GH deficiency diagnosis.

Despite improved GH-stimulating potency, GHRP-2 retains off-target effects on the HPA axis. Arvat et al. (1997) documented cortisol and ACTH co-elevation following GHRP-2 administration in healthy adults, attributing this to direct GHSR-1a or related receptor stimulation in adrenal tissue. Prolactin elevation has also been reported, though to a lesser degree than with GHRP-6. GHRP-2 does not substantially stimulate appetite or gastric motility at pharmacological doses, distinguishing it from GHRP-6 in this respect.

Ipamorelin: Selective GHSR-1a Agonism Without Cortisol or Prolactin Elevation

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) was developed by Novo Nordisk (formerly as part of their GHS program) and represents a significant advance in GHRP selectivity. The critical characterization study by Raun et al. (1998, European Journal of Endocrinology) systematically compared ipamorelin to GHRP-2 and GHRP-6 across a panel of hormonal endpoints in conscious swine and rat models.

Key findings from Raun et al. (1998):

Ipamorelin produced GH pulses of magnitude comparable to GHRP-2 at equivalent doses
Unlike GHRP-2 and GHRP-6, ipamorelin did not elevate plasma ACTH, cortisol, or prolactin at any tested dose
Ipamorelin did not elevate aldosterone — another adrenal endpoint assessed in the study
The selectivity of ipamorelin for GH release was therefore described as greater than that of any previously characterized synthetic GHRP
Food intake (appetite stimulation) was not observed, consistent with reduced ghrelin-like peripheral activity

The structural basis for ipamorelin's selectivity has been partially characterized through SAR studies. The Aib (alpha-aminoisobutyric acid) N-terminal substitution and D-2-naphthylalanine at position 3 appear to confer conformational rigidity that preferentially stabilizes receptor conformations coupled to GH secretion, with reduced engagement of signaling pathways linked to ACTH/cortisol release.

Ipamorelin has a plasma half-life of approximately 2 hours in rats, with similar estimates from limited human pharmacokinetic data. Like GHRP-2 and GHRP-6, it is susceptible to proteolytic degradation via aminopeptidases and endopeptidases.

Potency Ranking from Published Studies

Direct potency comparisons across the three peptides show a consistent rank order in acute GH release assays:

GHRP-2 ≥ Ipamorelin > GHRP-6 (GH-stimulating potency, equimolar doses)

However, potency rankings shift when comparing selectivity-adjusted effective doses (doses producing equivalent GH release without off-target hormonal effects):

Ipamorelin > GHRP-2 ≈ GHRP-6 (practical selectivity for GH-only endpoints)

Bowers (1998, Endocrine) summarized comparative GH secretagogue activity across the peptide GHS class in a landmark review, positioning GHRP-2 as the most potent acute GH releaser but noting that selectivity considerations favor ipamorelin in experimental models requiring clean GH axis isolation.

GHRP-6 Appetite and Gastric Motility Effects

The ghrelin-mimetic peripheral effects of GHRP-6 extend beyond appetite stimulation. In rodent models, GHRP-6 administration accelerates gastric emptying and stimulates gastrointestinal motility via vagal nerve pathways and direct enteric nervous system GHSR expression (Broglio et al., 2004, Journal of Clinical Endocrinology and Metabolism). This gastrokinetic profile has been proposed as potentially relevant for research in gastroparesis models, though dedicated controlled trials are lacking.

Calorie intake studies in rodents demonstrate that GHRP-6 increases 24-hour food consumption by 15–30% above vehicle, an effect that is blocked by GHSR-1a antagonists, confirming receptor dependence (Torsello et al., 2002, Endocrinology). This appetite effect is essentially absent with ipamorelin and substantially reduced with GHRP-2.

Selectivity Profile Comparison Table

Property	Ipamorelin	GHRP-2 (Pralmorelin)	GHRP-6
GHSR-1a binding affinity	~1–3 nM	~1–3 nM	~4–6 nM
GH-stimulating potency	High	High (slightly greater)	Moderate
Cortisol/ACTH elevation	Not observed (Raun 1998)	Yes — documented in humans	Yes — documented in humans
Prolactin elevation	Not observed	Mild elevation	Moderate elevation
Aldosterone elevation	Not observed	Not well characterized	Not well characterized
Appetite stimulation	Not observed	Minimal	Yes — dose-dependent
Gastric motility effects	Minimal	Minimal	Yes — ghrelin-like
Plasma half-life (approx.)	~2 hours	~1–2 hours	~1–2 hours
Clinical use (diagnostic)	Not approved	Approved in Japan (pralmorelin)	Not approved
Peptide selectivity class	Highly selective GH secretagogue	GH secretagogue (cortisol co-elevation)	Non-selective GHS/ghrelin mimetic
Research selectivity advantage	Highest (no HPA co-activation)	Intermediate	Lowest (multiple off-targets)

Conclusions from the Literature

Ipamorelin, GHRP-2, and GHRP-6 share the GHSR-1a receptor target but differ importantly in their selectivity profiles. For research models in which isolation of the GH secretory axis is paramount — and in which cortisol, prolactin, or appetite-related confounders would compromise endpoint interpretation — ipamorelin's published selectivity data (Raun et al., 1998) make it the preferred research tool among the three.

GHRP-2 offers the highest acute GH-stimulating potency and has the most extensive clinical pharmacology data, including approved diagnostic use in some countries, making it the most validated GHSR-1a agonist from a translational perspective despite its cortisol co-elevation.

GHRP-6 most closely replicates the pleiotropic receptor biology of endogenous ghrelin, making it the appropriate choice for research specifically targeting ghrelin-mimetic gastric motility, appetite, or energy balance pathways rather than isolated GH axis biology.

All three compounds are research-only agents with no current FDA approval for therapeutic use. Relevant studies should reference the primary Bowers laboratory and Raun et al. publications for selectivity characterization.